DOCSLIB.ORG

Predicting and Modifying Response to Neoadjuvant Therapy in Colorectal Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Predicting and Modifying Response to Neoadjuvant Therapy in Colorectal Cancer Predicting and modifying response to neoadjuvant therapy in colorectal cancer This thesis is submitted in accordance with the requirements of the University of Liverpool for the degree of Doctor in Philosophy By Paul Anthony Sutton September 2015 Dedication To my family. Without your love and support I would not be where I am today. i Declaration The work presented in this thesis was carried out in the Institute of Translational Medicine, University of Liverpool and was undertaken while working as a research fellow at the Liverpool Cancer Research (UK) Centre. The material contained within this thesis has not been, nor is currently being presented wholly, or in part, for any other degree or qualification. I declare that all the work presented in this thesis has been carried out by me except where indicated below: Cation exchange prior to iTRAQ analysis was performed by Mrs Jane Hamlett iTRAQ mass spectrometry was performed by Dr Roz Jenkins Assessment of radiological response was performed by Dr G Abbott Histopathological assessment of tumour response was performed by Dr M Terlizzo and Dr T Andrews Exome sequencing was performed at Genotypic Technology Paul Sutton ii Acknowledgments I am indebted to the many people who have helped me over the last few years. First and foremost my supervisors: Professor Dan Palmer, Dr Chris Goldring, Mr Hassan Malik and Mr Dale Vimalachandran. Thank you for your endless support, enthusiasm and patience as I attempted to make the transition from clinician to scientist. I’d also like to thank my ‘room-mate’, Dr Neil Kitteringham, who provided endless advice and guidance as well as acting as a sounding board and telling me when I was wrong. I feel extremely lucky to have been trained by you. One of the most challenging aspects of this work was the bioinformatics analysis, for which I am grateful for the time and assistance of Dr Puthen V Jithesh. I am also grateful to all the staff in the Medical Research Council Centre for Drug Safety Science who assisted me in the acquisition of laboratory technique, in particular Dr Cliff Rowe and Dr Jo Henry. The work presented in this thesis required the establishment of a regional network of colorectal surgeons to facilitate the recruitment of patients and collection of clinical samples. As such I am grateful to the following collaborators for their help and support: Trust Principal Investigator Royal Liverpool and Broadgreen Mr Paul Rooney Aintree University Hospital Mr Hassan Malik Countess of Chester Hospital Mr Dale Vimalachandran Arrowe Park Hospital Mr Ciaran Walsh Clatterbridge Centre for Oncology Professor Dan Palmer Mid Cheshire Hospital (Leighton) Mrs Caroline Bruce St Helens and Knowsley Hospital Mr Ajai Samad Liverpool Heart and Chest Hospital Mr Michael Shackcloth Southport and Ormskirk Mr Tarek Hany iii East Cheshire Hospital Mr Usman Khan Royal Bolton Hospital Mr David Smith North Wales Health Board Dr Simon Gollins Warrington and Halton Hospital Mr Mark Tighe My fellow surgical trainees have also made the research process much easier, and I wish to thank Mr Rob Jones, Mr Jonathan Evans, Mr Derek McWhirter, Mr David Bowden and Mr Declan Dunne. I am grateful to Professor John Neoptolemos both for his mentorship, and for affording me this opportunity. Finally I wish to thank Cancer Research (UK) who funded me and this work. iv Contents Dedication i Declaration ii Acknowledgements iii Contents v Abstract vii List of Tables viii List of Figures xv Abbreviations xxi Chapter 1 – General Introduction 1 1.1 Epidemiology of colorectal cancer 2 1.2 Risk factors for colorectal cancer 3 1.3 Genetics of colorectal cancer 3 1.4 Staging of colorectal cancer 9 1.5 Treatment of colorectal cancer with surgery 18 1.6 Treatment of colorectal cancer with radiotherapy 24 1.7 Chemotherapeutic agents used in colorectal cancer 29 1.8 Treatment of colorectal cancer with chemotherapy 35 1.9 Asssessment of response to chemoradiotherapy 43 1.10 Predictive and prognostic markers in colorectal cancer 49 1.11 Summary 58 1.12 Aims, hypotheses and study plan 59 Chapter 2 - Evaluation of a tissue stabilisation gel (AllprotectTM) to facilitate clinical sampling for translational research in surgical trials 63 2.1 Introduction 64 2.2 Methods 66 2.3 Results 71 2.4 Discussion 81 Chapter 3 - Exome sequencing of synchronously resected primary colorectal tumours and colorectal liver metastases to inform oncosurgical management 86 3.1 Introduction 87 3.2 Methods 91 3.3 Results 96 3.4 Discussion 117 v Chapter 4 - A global proteomic assessment of patient matched primary and metastatic colorectal tumours 126 4.1 Introduction 127 4.2 Methods 131 4.3 Results 137 4.4 Discussion 168 Chapter 5 - A global proteomic assessment of serial rectal tumour biopsies 177 5.1 Introduction 178 5.2 Methods 180 5.3 Results 184 5.4 Discussion 203 Chapter 6 – Targeted analysis of candidate biomarkers in the primary tumour for predicting response to neoadjuvant chemotherapy in colorectal liver metastases 208 6.1 Introduction 209 6.2 Methods 212 6.3 Results 226 6.4 Discussion 251 Chapter 7 – Concluding Discussion 261 7.1 Summary of aims and experimental design 262 7.2 Summary of results 263 7.3 Advances in the literature 267 7.4 Study limitations and further work 269 7.5 Review of hypotheses 270 7.6 Conclusions 271 Bibliography 273 Appendix 1 - Lists of single nucleotide variants from exome sequencing 299 Appendix 2 - Genetic variants in colorectal cancer identified by next generation sequencing studies 329 Appendix 3 - Proteomic comparison of metastatic tumour and normal adjacent liver parenchyma 337 Appendix 4 - Proteomic comparison of responders and non-responders in the primary tumour 353 Appendix 5 - Supporting Publications, Presentations, Prizes and Grants 361 vi Abstract Background Colorectal cancer is the fourth commonest cancer in the UK, and the second commonest cause of cancer-related death. A knowledge of the biology of colorectal liver metastases would be invaluable to inform clinical decision making; however, deriving this information from the metastatic lesions is not feasible until after resection. We aimed to use proteomic and genomic analysis to establish the degree of biological similarity across disease sites and identify biomarkers in the primary tumour which predict response to neoadjuvant chemotherapy in liver metastases. An identical approach was also used to identify predictors of response to neoadjuvant chemoradiotherapy in rectal cancer. Methods Fresh tissue from both primary colorectal tumour and liver metastases from 16 patients was subjected to proteomic analysis using isobaric tagging for relative quantification (iTRAQ). Data were analysed with Protein Pilot (Ab Sciex, Framingham, MA, USA), with stratification of patients into those showing low or high response to chemotherapy permitting the identification of potential predictive biomarkers. These markers were subsequently investigated by immunohistochemistry on a tissue microarray of 56 patients, in parallel with a series of in vitro studies to investigate the concordance between primary and metastatic tumours of those proteins relevant to the activation and metabolism of 5-FU, irinotecan and oxaliplatin. The therapeutic potential of the identified biomarkers was also investigated by dosing SW480 cells with irinotecan/5FU with or without inhibition (using siRNA or a known competitive inhibitor) of the proteins of interest. Four of the 16 patients studied were resected synchronously, and tissue from these was also used for exome sequencing using the Ion Proton platform. Diagnostic, post- treatment and resection biopsies from 8 patients with rectal cancer were again subjected to iTRAQ with stratification into low or high response to neoadjuvant chemoradiotherapy to investigate potential response biomarkers. Findings We identified 5766 discrete proteins, of which 2.54% were differentially expressed between primary and metastatic tumours. There were 170 potential response biomarkers in the primary tumour and 27 in the metastases. Two proteins were common to both tissue types and showed consistent dysregulation, including NQO1. Immunostaining of NQ01 in metastases revealed lower expression in patients responding to chemotherapy (p=0.041), with a significant correlation between primary and metastatic disease sites (r=0.44, p=0.001). Knockdown of NQO1 followed by treatment with irinotecan and 5FU reduced the IC50 from 100.1µM to 49.8µM and from 200.1µM to 25.0µM respectively. Pre-treating cells with dicoumarol prior to incubation in irinotecan and 5FU reduced the IC50 from 100.0µM to 50.0µM and from 183.7µM to 49.9µM respectively. Exome sequencing identified 585 non-synonymous missense SNVs of which 215 (36.8%) were unique to the primary tumour, 226 (38.6%) unique to the metastasis and 81 (13.8%) present in patient matched pairs. Aberrations in the ErbB pathway were identified in paired samples (ratio 0.07, p=5.87x10-7), which were validated by Sanger sequencing along with a potential response biomarker in the CDAN1 gene. Changes to the phenotype of the rectal tumour with chemoradiotherapy were modest, although it is clear that base excision repair (and in particular PARP1) remains of interest, and that acid ceramidase is a potential response biomarker and novel radiosensitiser. Interpretation Proteomic sequencing of matched metastatic colorectal cancer samples is feasible with high coverage. The high degree of similarity between the primary and secondary tumours suggests that the primary tissue is predictive of the metastatic phenotype. NQO1 expression in the primary tumour predicts response to neoadjuvant chemotherapy in the liver metastases, and inhibition of this protein at both genetic and functional levels improves chemosensitivity. vii List of Tables Table Legend Page 1.1 Percentage of cases and 5 year relative survival (%) by Dukes' stage at 2 diagnosis for colorectal cancer patients diagnosed 1996-2002 in England. (Reproduced without permission from Cancer Research (UK)). 1.2 Genetics of inherited colorectal tumour syndromes. (Reproduced without 4 permission from Fearon, 2011).
Load more

Recommended publications
  • 4-6 Weeks Old Female C57BL/6 Mice Obtained from Jackson Labs Were Used for Cell Isolation
    Methods Mice: 4-6 weeks old female C57BL/6 mice obtained from Jackson labs were used for cell isolation. Female Foxp3-IRES-GFP reporter mice (1), backcrossed to B6/C57 background for 10 generations, were used for the isolation of naïve CD4 and naïve CD8 cells for the RNAseq experiments. The mice were housed in pathogen-free animal facility in the La Jolla Institute for Allergy and Immunology and were used according to protocols approved by the Institutional Animal Care and use Committee. Preparation of cells: Subsets of thymocytes were isolated by cell sorting as previously described (2), after cell surface staining using CD4 (GK1.5), CD8 (53-6.7), CD3ε (145- 2C11), CD24 (M1/69) (all from Biolegend). DP cells: CD4+CD8 int/hi; CD4 SP cells: CD4CD3 hi, CD24 int/lo; CD8 SP cells: CD8 int/hi CD4 CD3 hi, CD24 int/lo (Fig S2). Peripheral subsets were isolated after pooling spleen and lymph nodes. T cells were enriched by negative isolation using Dynabeads (Dynabeads untouched mouse T cells, 11413D, Invitrogen). After surface staining for CD4 (GK1.5), CD8 (53-6.7), CD62L (MEL-14), CD25 (PC61) and CD44 (IM7), naïve CD4+CD62L hiCD25-CD44lo and naïve CD8+CD62L hiCD25-CD44lo were obtained by sorting (BD FACS Aria). Additionally, for the RNAseq experiments, CD4 and CD8 naïve cells were isolated by sorting T cells from the Foxp3- IRES-GFP mice: CD4+CD62LhiCD25–CD44lo GFP(FOXP3)– and CD8+CD62LhiCD25– CD44lo GFP(FOXP3)– (antibodies were from Biolegend). In some cases, naïve CD4 cells were cultured in vitro under Th1 or Th2 polarizing conditions (3, 4).
    [Show full text]
  • Anti-Inflammatory Role of Curcumin in LPS Treated A549 Cells at Global Proteome Level and on Mycobacterial Infection
    Anti-inflammatory Role of Curcumin in LPS Treated A549 cells at Global Proteome level and on Mycobacterial infection. Suchita Singh1,+, Rakesh Arya2,3,+, Rhishikesh R Bargaje1, Mrinal Kumar Das2,4, Subia Akram2, Hossain Md. Faruquee2,5, Rajendra Kumar Behera3, Ranjan Kumar Nanda2,*, Anurag Agrawal1 1Center of Excellence for Translational Research in Asthma and Lung Disease, CSIR- Institute of Genomics and Integrative Biology, New Delhi, 110025, India. 2Translational Health Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, 110067, India. 3School of Life Sciences, Sambalpur University, Jyoti Vihar, Sambalpur, Orissa, 768019, India. 4Department of Respiratory Sciences, #211, Maurice Shock Building, University of Leicester, LE1 9HN 5Department of Biotechnology and Genetic Engineering, Islamic University, Kushtia- 7003, Bangladesh. +Contributed equally for this work. S-1 70 G1 S 60 G2/M 50 40 30 % of cells 20 10 0 CURI LPSI LPSCUR Figure S1: Effect of curcumin and/or LPS treatment on A549 cell viability A549 cells were treated with curcumin (10 µM) and/or LPS or 1 µg/ml for the indicated times and after fixation were stained with propidium iodide and Annexin V-FITC. The DNA contents were determined by flow cytometry to calculate percentage of cells present in each phase of the cell cycle (G1, S and G2/M) using Flowing analysis software. S-2 Figure S2: Total proteins identified in all the three experiments and their distribution betwee curcumin and/or LPS treated conditions. The proteins showing differential expressions (log2 fold change≥2) in these experiments were presented in the venn diagram and certain number of proteins are common in all three experiments.
    [Show full text]
  • Detecting Substrate Glycans of Fucosyltransferases on Glycoproteins with Fluorescent Fucose
    bioRxiv preprint doi: https://doi.org/10.1101/2020.01.28.919860; this version posted January 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Detecting substrate glycans of fucosyltransferases on glycoproteins with fluorescent fucose Key words: Fucose/Fucosylation/fucosyltransferase/core-fucose/glycosylation Supplementary Data Included: Supplemental Fig.1 to Fig. 2 Zhengliang L Wu1*, Mark Whitaker, Anthony D Person1, Vassili Kalabokis1 1Bio-techne, R&D Systems, Inc. 614 McKinley Place N.E. Minneapolis, MN, 55413, USA *Correspondence: Phone: 612-656-4544. Email: [email protected], bioRxiv preprint doi: https://doi.org/10.1101/2020.01.28.919860; this version posted January 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract Like sialylation, fucose usually locates at the non-reducing ends of various glycans on glycoproteins and constitutes important glycan epitopes. Detecting the substrate glycans of fucosyltransferases is important for understanding how these glycan epitopes are regulated in response to different growth conditions and external stimuli. Here we report the detection of these glycans via enzymatic incorporation of fluorescent tagged fucose using fucosyltransferases including FUT2, FUT6, FUT7, and FUT8 and FUT9. More specifically, we describe the detection of substrate glycans of FUT8 and FUT9 on therapeutic antibodies and the detection of high mannose glycans on glycoproteins by enzymatic conversion of high mannose glycans to the substrate glycans of FUT8.
    [Show full text]
  • Enhancing the Thermostability and Activity of Uronate Dehydrogenase from Agrobacterium Tumefaciens LBA4404 by Semi-Rational Engi
    Su et al. Bioresour. Bioprocess. (2019) 6:36 https://doi.org/10.1186/s40643-019-0267-3 RESEARCH Open Access Enhancing the thermostability and activity of uronate dehydrogenase from Agrobacterium tumefaciens LBA4404 by semi-rational engineering Hui‑Hui Su1†, Fei Peng1†, Pei Xu1, Xiao‑Ling Wu1, Min‑Hua Zong1, Ji‑Guo Yang2 and Wen‑Yong Lou1* Abstract Background: Glucaric acid, one of the aldaric acids, has been declared a “top value‑added chemical from biomass”, and is especially important in the food and pharmaceutical industries. Biocatalytic production of glucaric acid from glucuronic acid is more environmentally friendly, efcient and economical than chemical synthesis. Uronate dehydro‑ genases (UDHs) are the key enzymes for the preparation of glucaric acid in this way, but the poor thermostability and low activity of UDH limit its industrial application. Therefore, improving the thermostability and activity of UDH, for example by semi‑rational design, is a major research goal. Results: In the present work, three UDHs were obtained from diferent Agrobacterium tumefaciens strains. The three UDHs have an approximate molecular weight of 32 kDa and all contain typically conserved UDH motifs. All three UDHs showed optimal activity within a pH range of 6.0–8.5 and at a temperature of 30 °C, but the UDH from A. tume- 1 1 faciens (At) LBA4404 had a better catalytic efciency than the other two UDHs (800 vs 600 and 530 s− mM− ). To fur‑ ther boost the catalytic performance of the UDH from AtLBA4404, site‑directed mutagenesis based on semi‑rational design was carried out. An A39P/H99Y/H234K triple mutant showed a 400‑fold improvement in half‑life at 59 °C, a 10 5 °C improvement in T50 value and a 2.5‑fold improvement in specifc activity at 30 °C compared to wild‑type UDH.
    [Show full text]
  • Tumor Growth and Cancer Treatment
    Molecular Cochaperones: Tumor Growth and Cancer Treatment The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Calderwood, Stuart K. 2013. “Molecular Cochaperones: Tumor Growth and Cancer Treatment.” Scientifica 2013 (1): 217513. doi:10.1155/2013/217513. http://dx.doi.org/10.1155/2013/217513. Published Version doi:10.1155/2013/217513 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879066 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Hindawi Publishing Corporation Scientifica Volume 2013, Article ID 217513, 13 pages http://dx.doi.org/10.1155/2013/217513 Review Article Molecular Cochaperones: Tumor Growth and Cancer Treatment Stuart K. Calderwood Division of Molecular and Cellular Biology, Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, 99 Brookline Avenue, Boston, MA 02215, USA Correspondence should be addressed to Stuart K. Calderwood; [email protected] Received 11 February 2013; Accepted 1 April 2013 Academic Editors: M. H. Manjili and Y. Oji Copyright © 2013 Stuart K. Calderwood. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Molecular chaperones play important roles in all cellular organisms by maintaining the proteome in an optimally folded state. They appear to be at a premium in cancer cells whose evolution along the malignant pathways requires the fostering of cohorts of mutant proteins that are employed to overcome tumor suppressive regulation.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0082511 A1 Brown Et Al
    US 20030082511A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0082511 A1 Brown et al. (43) Pub. Date: May 1, 2003 (54) IDENTIFICATION OF MODULATORY Publication Classification MOLECULES USING INDUCIBLE PROMOTERS (51) Int. Cl." ............................... C12O 1/00; C12O 1/68 (52) U.S. Cl. ..................................................... 435/4; 435/6 (76) Inventors: Steven J. Brown, San Diego, CA (US); Damien J. Dunnington, San Diego, CA (US); Imran Clark, San Diego, CA (57) ABSTRACT (US) Correspondence Address: Methods for identifying an ion channel modulator, a target David B. Waller & Associates membrane receptor modulator molecule, and other modula 5677 Oberlin Drive tory molecules are disclosed, as well as cells and vectors for Suit 214 use in those methods. A polynucleotide encoding target is San Diego, CA 92121 (US) provided in a cell under control of an inducible promoter, and candidate modulatory molecules are contacted with the (21) Appl. No.: 09/965,201 cell after induction of the promoter to ascertain whether a change in a measurable physiological parameter occurs as a (22) Filed: Sep. 25, 2001 result of the candidate modulatory molecule. Patent Application Publication May 1, 2003 Sheet 1 of 8 US 2003/0082511 A1 KCNC1 cDNA F.G. 1 Patent Application Publication May 1, 2003 Sheet 2 of 8 US 2003/0082511 A1 49 - -9 G C EH H EH N t R M h so as se W M M MP N FIG.2 Patent Application Publication May 1, 2003 Sheet 3 of 8 US 2003/0082511 A1 FG. 3 Patent Application Publication May 1, 2003 Sheet 4 of 8 US 2003/0082511 A1 KCNC1 ITREXCHO KC 150 mM KC 2000000 so 100 mM induced Uninduced Steady state O 100 200 300 400 500 600 700 Time (seconds) FIG.
    [Show full text]
  • Whole Exome Sequencing in Families at High Risk for Hodgkin Lymphoma: Identification of a Predisposing Mutation in the KDR Gene
    Hodgkin Lymphoma SUPPLEMENTARY APPENDIX Whole exome sequencing in families at high risk for Hodgkin lymphoma: identification of a predisposing mutation in the KDR gene Melissa Rotunno, 1 Mary L. McMaster, 1 Joseph Boland, 2 Sara Bass, 2 Xijun Zhang, 2 Laurie Burdett, 2 Belynda Hicks, 2 Sarangan Ravichandran, 3 Brian T. Luke, 3 Meredith Yeager, 2 Laura Fontaine, 4 Paula L. Hyland, 1 Alisa M. Goldstein, 1 NCI DCEG Cancer Sequencing Working Group, NCI DCEG Cancer Genomics Research Laboratory, Stephen J. Chanock, 5 Neil E. Caporaso, 1 Margaret A. Tucker, 6 and Lynn R. Goldin 1 1Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 2Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 3Ad - vanced Biomedical Computing Center, Leidos Biomedical Research Inc.; Frederick National Laboratory for Cancer Research, Frederick, MD; 4Westat, Inc., Rockville MD; 5Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; and 6Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA ©2016 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.135475 Received: August 19, 2015. Accepted: January 7, 2016. Pre-published: June 13, 2016. Correspondence: [email protected] Supplemental Author Information: NCI DCEG Cancer Sequencing Working Group: Mark H. Greene, Allan Hildesheim, Nan Hu, Maria Theresa Landi, Jennifer Loud, Phuong Mai, Lisa Mirabello, Lindsay Morton, Dilys Parry, Anand Pathak, Douglas R. Stewart, Philip R. Taylor, Geoffrey S. Tobias, Xiaohong R. Yang, Guoqin Yu NCI DCEG Cancer Genomics Research Laboratory: Salma Chowdhury, Michael Cullen, Casey Dagnall, Herbert Higson, Amy A.
    [Show full text]
  • A-Transferase, 338 ABO Blood Group System, 330 and Cloning, 338
    Index A-transferase, 338 ALG9,165 ABO blood group system, 330 ALGlO,168 and cloning, 338 genetic basis of, 22 B-transferase, 338 activated oligosaccharides bacterial S-Iayers in glycopeptide synthesis, 466, 470 glycosylation in, 439 2-aminoethylphosphonate bacterial toxins in invertebrate glycoproteins, 420 and glycosylation, 413 anomer, 5 biological macromolecules formal defmition of, 6 the four groups of, 2 Hudson definition of, 6 bird's nest soup, 16 anomeric carbon blood group antigens, 22 in synthesis, 459 and cancer, 23 anomeric effect, 8 prognostic value of, 23 anomeric oxygen exchange reactions, blood typing, 22 460,461 ABO system of, 22 anomeric oxygen-retaining reactions, 460, Lewis system of, 22 464 Bombay blood group, 331, 336, 348 antennae Bombay phenotype, 22 definition of, 10 branch specificity, 93 J3-arabinofuranose in plants, 418 caeruloplasmin, 23 asialoglycoprotein receptor, 494 calnexin, 54, 182 asparagine-linked glycosylation genes calreticulin, 54, 182, 188 ALGI, 158 capillary electrophoresis, 457 ALG2,161 carbohydrate metabolism, 1, 17 ALG3,165 Carbohydrate-Deficient Glycoprotein ALG5,167 Syndrome (COGS) Type 1, 152 ALG6,168 Carbohydrate-Deficient Glycoprotein ALG7,155 Syndrome (COGS) Type II, 226 ALGB,168 500 Index Carbohydrates; See a/so oligosaccharides deoxymannoj irimycin, 191 as molecules with key biological deoxynojirimycin, 184 functions, 3 dietary sugars, 1 biology of, 2 disaccharides covalent attachment to protein, 17 structural determination of, 17 definition of, 4 DNA,1 in bacterial and viral infection,
    [Show full text]
  • Toxicogenomic Approach to Impact Assessment of Whole Wastewater Effluents and Development of Effluent- Title Responsive Biomarker
    Toxicogenomic Approach to Impact Assessment of Whole Wastewater Effluents and Development of Effluent- Title Responsive Biomarker Author(s) 山村, 宏江 Citation 北海道大学. 博士(工学) 甲第11137号 Issue Date 2013-09-25 DOI 10.14943/doctoral.k11137 Doc URL http://hdl.handle.net/2115/77180 Type theses (doctoral) File Information Hiroe_Yamamura.pdf Instructions for use Hokkaido University Collection of Scholarly and Academic Papers : HUSCAP Doctoral Thesis Toxicogenomic Approach to Impact Assessment of Whole Wastewater Effluents and Development of Effluent-Responsive Biomarker Hiroe Hara-Yamamura Acknowledgement My doctoral research works presented here cannot be completed without a numerous number of tangible and intangible supports from my peers, my supervisor, instructors, friends, and family. I would first express my deepest gratitude to Prof. Satoshi OKABE for his technical advices and crisp ideas which often came to break the deadlock of my research progress, and for continued provision of another chance to me, even in the least fruitful season. Indeed, my three years in Prof. OKABE’s lab was “luxuri- ous” time in my life with a lot of supports, encouragements, and chances. In addition, I appreciate both Prof. Daisuke SANO and Dr. Satoshi ISHII for offering their insights on my experimental design and data analysis as well as giving me words of encouragements from time to time. Also, thank you to Prof. Takashi KUSUI from Toyama Prefectural University for his assistance to bioassay techniques and valuable discussion dur- ing my 1st year and 2nd year evaluation presentations. Furthermore, I would like to express my gratitude to specific efforts kindly provide by: Mr. Kenzo Kudo, Prof.
    [Show full text]
  • CDG and Immune Response: from Bedside to Bench and Back Authors
    CDG and immune response: From bedside to bench and back 1,2,3 1,2,3,* 2,3 1,2 Authors: Carlota Pascoal , Rita Francisco , Tiago Ferro , Vanessa dos Reis Ferreira , Jaak Jaeken2,4, Paula A. Videira1,2,3 *The authors equally contributed to this work. 1 Portuguese Association for CDG, Lisboa, Portugal 2 CDG & Allies – Professionals and Patient Associations International Network (CDG & Allies – PPAIN), Caparica, Portugal 3 UCIBIO, Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal 4 Center for Metabolic Diseases, UZ and KU Leuven, Leuven, Belgium Word count: 7478 Number of figures: 2 Number of tables: 3 This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/jimd.12126 This article is protected by copyright. All rights reserved. Abstract Glycosylation is an essential biological process that adds structural and functional diversity to cells and molecules, participating in physiological processes such as immunity. The immune response is driven and modulated by protein-attached glycans that mediate cell-cell interactions, pathogen recognition and cell activation. Therefore, abnormal glycosylation can be associated with deranged immune responses. Within human diseases presenting immunological defects are Congenital Disorders of Glycosylation (CDG), a family of around 130 rare and complex genetic diseases. In this review, we have identified 23 CDG with immunological involvement, characterised by an increased propensity to – often life-threatening – infection.
    [Show full text]
  • Nutrigenomics
    Nutrigenomics Carsten Carlberg • Stine Marie Ulven Ferdinand Molnár Nutrigenomics Carsten Carlberg Stine Marie Ulven Institute of Biomedicine Department of Nutrition University of Eastern Finland University of Oslo Kuopio , Finland Oslo , Norway Ferdinand Molnár School of Pharmacy University of Easterm Finland Kuopio , Finland ISBN 978-3-319-30413-7 ISBN 978-3-319-30415-1 (eBook) DOI 10.1007/978-3-319-30415-1 Library of Congress Control Number: 2016939131 © Springer International Publishing Switzerland 2016 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifi cally the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfi lms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specifi c statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. Printed on acid-free paper This Springer imprint is published by Springer Nature The registered company is Springer International Publishing AG Switzerland Pref ace Our daily diet is more than a collection of carbohydrates, lipids and proteins that provide energy and serve as building blocks of our life; our diet is also the most dominant environmental signal to which we are exposed from womb to death.
    [Show full text]
  • Global Regulation of Differential Gene Expression by C-Abl/Arg Oncogenic
    LAB/IN VITRO RESEARCH e-ISSN 1643-3750 © Med Sci Monit, 2017; 23: 2625-2635 DOI: 10.12659/MSM.904888 Received: 2017.04.16 Accepted: 2017.05.08 Global Regulation of Differential Gene Published: 2017.05.30 Expression by c-Abl/Arg Oncogenic Kinases Authors’ Contribution: ABCE 1 Qincai Dong* 1 Laboratory of Genetic Engineering, Beijing Institute of Biotechnology, Beijing, Study Design A BC 2 Chenggong Li* P.R. China Data Collection B 2 Institute of Health Sciences, Anhui University, Hefei, Anhui, P.R. China Statistical Analysis C BC 3 Xiuhua Qu 3 Center of Basic Medical Sciences, Navy General Hospital of PLA, Beijing, Data Interpretation D AFG 1 Cheng Cao P.R. China Manuscript Preparation E AEG 1 Xuan Liu Literature Search F Funds Collection G * These 2 authors contributed equally to this work Corresponding Authors: Xuan Liu, e-mail: [email protected], Cheng Cao, e-mail: [email protected] Source of support: This work was supported by the National Natural Science Foundation of China [31070674] Background: Studies have found that c-Abl oncogenic kinases may regulate gene transcription by RNA polymerase II phos- phorylation or by direct regulation of specific transcription factors or coactivators. However, the global regu- lation of differential gene expression by c-Abl/Arg is largely unknown. In this study, differentially expressed genes (DEGs) regulated by c-Abl/Arg were identified, and related cellular functions and associated pathways were investigated. Material/Methods: RNA obtained from wild-type and c-Abl/Arg gene-silenced MCF-7 cells was analyzed by RNA-Seq. DEGs were identified using edgeR software and partially validated by qRT-PCR.
    [Show full text]